patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_434993 | REC_0011001 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 3.6 | 65 | female | 1 | 60 | 4.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 15.6 | true | MSS | 2026-03-15T05:35:59.607658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217936 | REC_0011002 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 9.2 | 68 | female | 0 | 19 | 4.3 | 4 | pembrolizumab 200 mg q3w | 15.9 | false | MSS | 2026-03-15T05:35:59.607899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418472 | REC_0011003 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 13 | 74 | female | 2 | 13 | 5 | 1 | osimertinib 80 mg daily | 19.2 | true | MSS | 2026-03-15T05:35:59.608330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464181 | REC_0011004 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.3 | 70 | male | 3 | 69 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.4 | false | MSS | 2026-03-15T05:35:59.608619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567640 | REC_0011005 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.4 | 81 | female | 2 | 15 | 2.9 | 6 | alectinib 600 mg BID | 8.6 | true | MSS | 2026-03-15T05:35:59.608894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829725 | REC_0011006 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 13.8 | 78 | female | 2 | 9 | 4.9 | 5 | pembrolizumab 200 mg q3w | 11.7 | false | MSS | 2026-03-15T05:35:59.609162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541489 | REC_0011007 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 7.6 | 62 | male | 1 | 0 | 5 | 1 | pembrolizumab 200 mg q3w | 18.9 | true | MSS | 2026-03-15T05:35:59.609432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970292 | REC_0011008 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 14 | 12.1 | 66 | female | 0 | 23 | 4.8 | 5 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:35:59.609708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180470 | REC_0011009 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 12.5 | 68 | female | 1 | 7 | 5.7 | 3 | alectinib 600 mg BID | 17.7 | true | MSI-H | 2026-03-15T05:35:59.609962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646009 | REC_0011010 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.3 | 66 | female | 0 | 9 | 4.3 | 7 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:59.610200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558812 | REC_0011011 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 2.3 | 58 | female | 1 | 11 | 6.9 | 3 | pembrolizumab 200 mg q3w | 10.6 | false | MSS | 2026-03-15T05:35:59.610440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500436 | REC_0011012 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.9 | 68 | female | 0 | 36 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.9 | false | MSS | 2026-03-15T05:35:59.610798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105004 | REC_0011013 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 33 | 5.7 | 60 | male | 0 | 65 | 8.3 | 5 | pembrolizumab 200 mg q3w | 8.8 | false | MSS | 2026-03-15T05:35:59.611052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144990 | REC_0011014 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 12.7 | 80 | female | 2 | 4 | 4.4 | 5 | osimertinib 80 mg daily | 7.3 | true | MSS | 2026-03-15T05:35:59.611303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865373 | REC_0011015 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 4.1 | 59 | male | 1 | 74 | 4.7 | 7 | pembrolizumab 200 mg q3w | 12.8 | false | MSS | 2026-03-15T05:35:59.611559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365744 | REC_0011016 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 6 | 77 | female | 2 | 68 | 4.2 | 1 | pembrolizumab 200 mg q3w | 24.5 | false | MSS | 2026-03-15T05:35:59.611800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942302 | REC_0011017 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 12.3 | 76 | female | 1 | 17 | 5.5 | 1 | entrectinib 600 mg daily | 19.3 | false | MSS | 2026-03-15T05:35:59.612037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814412 | REC_0011018 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 11.9 | 83 | male | 1 | 21 | 4.9 | 1 | osimertinib 80 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:59.612340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814435 | REC_0011019 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 6.6 | 73 | female | 2 | 14 | 5.2 | 4 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:59.612607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939233 | REC_0011020 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 16 | 56 | male | 1 | 20 | 4.9 | 3 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:59.612895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987810 | REC_0011021 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 13.8 | 68 | male | 0 | 13 | 4 | 4 | entrectinib 600 mg daily | 15.4 | true | MSI-H | 2026-03-15T05:35:59.613199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245700 | REC_0011022 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 3.3 | 72 | female | 1 | 28 | 4.4 | 8 | carboplatin + paclitaxel + pembrolizumab | 7.3 | false | MSS | 2026-03-15T05:35:59.613495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720849 | REC_0011023 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 8.9 | 62 | male | 0 | 12 | 5.6 | 3 | osimertinib 80 mg daily | 21 | true | MSS | 2026-03-15T05:35:59.613773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327094 | REC_0011024 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 14.4 | 57 | female | 1 | 22 | 5.1 | 1 | pembrolizumab 200 mg q3w | 13.6 | true | MSS | 2026-03-15T05:35:59.614060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739928 | REC_0011025 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 16.5 | 65 | female | 1 | 10 | 5.6 | 1 | alectinib 600 mg BID | 24.4 | false | MSS | 2026-03-15T05:35:59.614546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488807 | REC_0011026 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 11.7 | 72 | female | 1 | 16 | 6.4 | 1 | osimertinib 80 mg daily | 19.5 | false | MSS | 2026-03-15T05:35:59.614878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940971 | REC_0011027 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 14.8 | 64 | male | 0 | 11 | 4.8 | 6 | alectinib 600 mg BID | 11.3 | false | MSI-H | 2026-03-15T05:35:59.615322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551831 | REC_0011028 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 14.3 | 65 | female | 1 | 19 | 5.9 | 6 | osimertinib 80 mg daily | 16.5 | false | MSI-H | 2026-03-15T05:35:59.615627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150887 | REC_0011029 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 8.3 | 64 | male | 0 | 24 | 5.7 | 2 | sotorasib 960 mg daily | 18.8 | true | MSS | 2026-03-15T05:35:59.615912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576385 | REC_0011030 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 10 | 63 | female | 1 | 22 | 5.1 | 3 | sotorasib 960 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:59.616295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797616 | REC_0011031 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 8.3 | 77 | female | 3 | 17 | 4.6 | 7 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:59.616602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649056 | REC_0011032 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 8 | 3.9 | 69 | female | 1 | 47 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.4 | false | MSS | 2026-03-15T05:35:59.616894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319040 | REC_0011033 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 17.2 | 55 | female | 0 | 10 | 4 | 2 | osimertinib 80 mg daily | 16.9 | true | MSS | 2026-03-15T05:35:59.617189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356250 | REC_0011034 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 18 | 5.6 | 73 | female | 0 | 71 | 6.3 | 1 | pembrolizumab 200 mg q3w | 7.5 | false | MSS | 2026-03-15T05:35:59.617474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681489 | REC_0011035 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 12.1 | 61 | male | 0 | 13 | 5 | 5 | osimertinib 80 mg daily | 10.1 | true | MSI-H | 2026-03-15T05:35:59.617763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394665 | REC_0011036 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 17 | 69 | male | 1 | 17 | 5.7 | 5 | osimertinib 80 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:59.618057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197305 | REC_0011037 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 11.2 | 80 | female | 0 | 22 | 6.1 | 6 | entrectinib 600 mg daily | 20.3 | false | MSS | 2026-03-15T05:35:59.618365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884711 | REC_0011038 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.3 | 69 | female | 0 | 8 | 5.6 | 4 | osimertinib 80 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:35:59.618836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873679 | REC_0011039 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 12.6 | 74 | female | 0 | 15 | 9 | 3 | entrectinib 600 mg daily | 10.1 | false | MSS | 2026-03-15T05:35:59.619208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455848 | REC_0011040 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 13.2 | 70 | female | 1 | 17 | 8.1 | 2 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:59.619532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456219 | REC_0011041 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 6.8 | 77 | female | 1 | 7 | 6.2 | 2 | osimertinib 80 mg daily | 27.7 | true | MSS | 2026-03-15T05:35:59.619831+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455150 | REC_0011042 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 14.9 | 64 | male | 1 | 16 | 5.2 | 5 | alectinib 600 mg BID | 8.3 | true | MSI-H | 2026-03-15T05:35:59.620217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610429 | REC_0011043 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 7 | 82 | female | 2 | 20 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.4 | false | MSS | 2026-03-15T05:35:59.620522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656416 | REC_0011044 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 3.8 | 72 | female | 2 | 51 | 4 | 6 | pembrolizumab 200 mg q3w | 15.1 | false | MSS | 2026-03-15T05:35:59.620815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345355 | REC_0011045 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 16 | 69 | female | 1 | 18 | 3.9 | 4 | sotorasib 960 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:59.621109+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257725 | REC_0011046 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 12.7 | 61 | male | 1 | 13 | 3.5 | 1 | alectinib 600 mg BID | 24.9 | false | MSI-H | 2026-03-15T05:35:59.621370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_523588 | REC_0011047 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4 | 64 | female | 0 | 47 | 3.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSS | 2026-03-15T05:35:59.621616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160355 | REC_0011048 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 16.3 | 67 | female | 0 | 20 | 6.4 | 5 | alectinib 600 mg BID | 11.7 | true | MSS | 2026-03-15T05:35:59.621852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303475 | REC_0011049 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 15 | 60 | female | 1 | 17 | 5.8 | 2 | sotorasib 960 mg daily | 20.4 | false | MSI-H | 2026-03-15T05:35:59.622090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441132 | REC_0011050 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7.1 | 73 | female | 2 | 48 | 6.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 27.6 | false | MSS | 2026-03-15T05:35:59.622320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687287 | REC_0011051 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 12.1 | 84 | male | 2 | 12 | 3 | 3 | pembrolizumab 200 mg q3w | 20.2 | false | MSI-H | 2026-03-15T05:35:59.622671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583339 | REC_0011052 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 13.6 | 65 | female | 0 | 19 | 5.9 | 4 | sotorasib 960 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:59.622913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322480 | REC_0011053 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.5 | 64 | female | 1 | 6 | 6.4 | 3 | alectinib 600 mg BID | 15.2 | true | MSS | 2026-03-15T05:35:59.623153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708488 | REC_0011054 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 9.9 | 65 | male | 1 | 20 | 4.7 | 5 | entrectinib 600 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:59.623389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985802 | REC_0011055 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 13.7 | 68 | female | 1 | 14 | 5.9 | 2 | pembrolizumab 200 mg q3w | 18.6 | false | MSS | 2026-03-15T05:35:59.623624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187538 | REC_0011056 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.3 | 76 | female | 1 | 15 | 6.2 | 5 | osimertinib 80 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:59.623855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248943 | REC_0011057 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 9.1 | 69 | female | 1 | 13 | 5 | 2 | sotorasib 960 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:59.624131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284349 | REC_0011058 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 6 | 57 | female | 1 | 21 | 4.6 | 5 | sotorasib 960 mg daily | 7.4 | true | MSS | 2026-03-15T05:35:59.624383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341212 | REC_0011059 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 20 | 4 | 67 | female | 0 | 14 | 4.1 | 0 | pembrolizumab 200 mg q3w | 72 | false | MSS | 2026-03-15T05:35:59.624627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495906 | REC_0011060 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.1 | 59 | male | 0 | 66 | 3.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.3 | true | MSS | 2026-03-15T05:35:59.624859+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_642083 | REC_0011061 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12.6 | 80 | female | 1 | 24 | 7.3 | 1 | osimertinib 80 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:35:59.625089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192697 | REC_0011062 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 17.4 | 56 | female | 0 | 14 | 4.4 | 1 | alectinib 600 mg BID | 18.9 | true | MSI-H | 2026-03-15T05:35:59.625323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994659 | REC_0011063 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 14.1 | 82 | female | 2 | 14 | 6.6 | 1 | entrectinib 600 mg daily | 15.7 | true | MSS | 2026-03-15T05:35:59.625556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534168 | REC_0011064 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 7.6 | 54 | female | 0 | 14 | 5.6 | 7 | entrectinib 600 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:59.625844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128887 | REC_0011065 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.2 | 71 | female | 1 | 61 | 3.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.4 | false | MSS | 2026-03-15T05:35:59.626083+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486192 | REC_0011066 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 12.7 | 78 | female | 1 | 14 | 3.9 | 2 | pembrolizumab 200 mg q3w | 8.6 | false | MSS | 2026-03-15T05:35:59.626317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140627 | REC_0011067 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 8.6 | 77 | female | 2 | 15 | 4.9 | 2 | osimertinib 80 mg daily | 23.7 | true | MSS | 2026-03-15T05:35:59.626546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844779 | REC_0011068 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 19 | 6.3 | 74 | female | 2 | 29 | 5.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 39.2 | false | MSS | 2026-03-15T05:35:59.626781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309934 | REC_0011069 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 10.9 | 62 | female | 0 | 15 | 4.4 | 2 | sotorasib 960 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:35:59.627032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623098 | REC_0011070 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.6 | 56 | female | 1 | 46 | 2.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 6.6 | true | MSS | 2026-03-15T05:35:59.627272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527568 | REC_0011071 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 29 | 9.3 | 66 | male | 0 | 18 | 6.6 | 0 | pembrolizumab 200 mg q3w | 25.6 | false | MSS | 2026-03-15T05:35:59.627515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303422 | REC_0011072 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 10.7 | 80 | female | 2 | 5 | 5.5 | 5 | entrectinib 600 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:35:59.628014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144001 | REC_0011073 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 15.2 | 63 | male | 0 | 25 | 6.6 | 7 | sotorasib 960 mg daily | 5 | true | MSS | 2026-03-15T05:35:59.628456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482013 | REC_0011074 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 7.3 | 76 | female | 2 | 15 | 7.5 | 4 | osimertinib 80 mg daily | 21.7 | true | MSS | 2026-03-15T05:35:59.628729+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748158 | REC_0011075 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 3.7 | 73 | female | 2 | 62 | 3.8 | 9 | carboplatin + paclitaxel + pembrolizumab | 15.3 | true | MSS | 2026-03-15T05:35:59.629010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862712 | REC_0011076 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 5.6 | 65 | female | 1 | 62 | 4 | 3 | carboplatin + paclitaxel + pembrolizumab | 6.1 | false | MSS | 2026-03-15T05:35:59.629268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746433 | REC_0011077 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.3 | 64 | male | 1 | 32 | 4.5 | 8 | carboplatin + paclitaxel + pembrolizumab | 7.7 | false | MSS | 2026-03-15T05:35:59.629639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744052 | REC_0011078 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 14.1 | 77 | female | 1 | 17 | 5.4 | 2 | osimertinib 80 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:59.629886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935771 | REC_0011079 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 12.6 | 60 | male | 1 | 19 | 6 | 2 | osimertinib 80 mg daily | 21.4 | false | MSI-H | 2026-03-15T05:35:59.630147+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577892 | REC_0011080 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 14.7 | 58 | male | 0 | 22 | 5.5 | 4 | entrectinib 600 mg daily | 7.8 | false | MSS | 2026-03-15T05:35:59.630387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621868 | REC_0011081 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 11.4 | 65 | female | 0 | 15 | 4.8 | 8 | osimertinib 80 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:35:59.630627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535948 | REC_0011082 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.7 | 69 | female | 0 | 23 | 7.8 | 5 | pembrolizumab 200 mg q3w | 15.6 | false | MSS | 2026-03-15T05:35:59.630857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345372 | REC_0011083 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 6.4 | 62 | male | 0 | 17 | 5.4 | 8 | osimertinib 80 mg daily | 17 | false | MSS | 2026-03-15T05:35:59.631091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414175 | REC_0011084 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 16.3 | 72 | female | 1 | 7 | 4.5 | 7 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:59.631324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387912 | REC_0011085 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 11 | 6.4 | 71 | female | 2 | 35 | 6.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:35:59.631554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811922 | REC_0011086 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.7 | 55 | male | 1 | 22 | 6.2 | 5 | pembrolizumab 200 mg q3w | 17.7 | false | MSS | 2026-03-15T05:35:59.631785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720560 | REC_0011087 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 18.5 | 66 | female | 0 | 15 | 5.5 | 8 | alectinib 600 mg BID | 7.4 | false | MSI-H | 2026-03-15T05:35:59.632028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_145154 | REC_0011088 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.6 | 64 | female | 1 | 33 | 5.1 | 6 | osimertinib 80 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:59.632321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795682 | REC_0011089 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 10.2 | 69 | female | 1 | 22 | 6.2 | 7 | entrectinib 600 mg daily | 12 | false | MSS | 2026-03-15T05:35:59.632569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_206537 | REC_0011090 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 11.5 | 67 | male | 0 | 18 | 4.6 | 4 | alectinib 600 mg BID | 9.9 | false | MSI-H | 2026-03-15T05:35:59.632889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812089 | REC_0011091 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.5 | 67 | male | 0 | 15 | 3.7 | 5 | osimertinib 80 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:59.633133+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743726 | REC_0011092 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 11.6 | 60 | female | 1 | 10 | 5.3 | 7 | alectinib 600 mg BID | 6.2 | true | MSS | 2026-03-15T05:35:59.633372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781652 | REC_0011093 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 13.1 | 68 | female | 1 | 6 | 3.4 | 8 | osimertinib 80 mg daily | 16.9 | false | MSS | 2026-03-15T05:35:59.633609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182403 | REC_0011094 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 10.2 | 68 | female | 1 | 10 | 6.1 | 7 | entrectinib 600 mg daily | 13.7 | true | MSI-H | 2026-03-15T05:35:59.633844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656120 | REC_0011095 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 11.9 | 61 | female | 1 | 16 | 4.7 | 1 | osimertinib 80 mg daily | 14.4 | true | MSS | 2026-03-15T05:35:59.634079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121150 | REC_0011096 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.1 | 70 | female | 1 | 14 | 5.3 | 2 | osimertinib 80 mg daily | 8.4 | true | MSS | 2026-03-15T05:35:59.634310+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939758 | REC_0011097 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 14.5 | 59 | female | 1 | 14 | 7.2 | 1 | pembrolizumab 200 mg q3w | 14.2 | false | MSI-H | 2026-03-15T05:35:59.634545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609343 | REC_0011098 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 8.5 | 67 | female | 1 | 15 | 4.6 | 1 | sotorasib 960 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:59.634771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454500 | REC_0011099 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 7.7 | 63 | female | 0 | 16 | 4.8 | 1 | sotorasib 960 mg daily | 10 | false | MSS | 2026-03-15T05:35:59.635002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107886 | REC_0011100 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 13.5 | 62 | female | 0 | 9 | 5.5 | 4 | sotorasib 960 mg daily | 8.7 | false | MSS | 2026-03-15T05:35:59.635245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.